Trial Profile
A Phase I Study of Nivolumab in Combination With Escalating Doses of Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 30 Nov 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Plinabulin (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 21 Nov 2022 Status changed from recruiting to active, no longer recruiting.
- 22 Feb 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2022.
- 05 Dec 2019 Planned End Date changed from 1 Dec 2020 to 1 Dec 2022.